From 17th to 20th September, the international biopharma and biotechnology community will converge on Shanghai for BioShanghai Week 2026 – one of the most significant gatherings in the global...
Every year, thousands of promising therapeutic discoveries stall somewhere between the lab bench and the clinic. The science is sound. The mechanism is proven. But something in the translation –...
Micregen, the UK-based biotechnology company pioneering stem cell secretome technology, has presented new preclinical research findings at the 4th Edition Global Longevity Federation Conference, where...
We are thrilled to celebrate Micregen’s very own Andrew Parnell, who successfully defended his PhD thesis at the University of Reading on 28th November. Andrew’s research, titled “Development of a...
What a fantastic day at LSX Investival Conference 2025! We were proud to have Robert Mitchell, & Ben Mellows there who delivered an excellent showcase presentation highlighting the science...
At Micregen, we’ve always believed that great science and smart technology go hand in hand. Our mission to advance stem cell–derived therapies is built on combining deep biological expertise with the...
Rare Disease Day 2025 is marked today on the 28th of February and everyone at Micregen stand in solidarity with the 300 million people, their families & carers globally affected by rare and...
Barry Sharples, our Executive Chairman and Co-founder, was one of 10 exclusive global speakers invited to pitch at the invite-only 2024 Longevity Investors Conference in Gstaad, Switzerland. This was...
Micregen is pleased to announce its sponsorship of the 37th International Symposium on Pediatrics Surgical Research 2024, to be held at the Karolinska Institute in Stockholm, Sweden. This conference...